• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail

GRN No. 714

Subtilisin from Bacillus amyloliquefaciens produced in Bacillus subtilis

Intended Use: For use in the processing of protein at 58-369 mg TOS/kg substrate to facilitate protein hydrolysis.
Basis: Scientific procedures
Notifier: Danisco US Inc. (Dupont Industrial Biosciences)
Notifier Address: 925 Page Mill Road
Palo Alto, CA, 94304
GRAS Notice (releasable information): GRN 714 (in PDF) (10.8 MB)
Date of closure: Feb 6, 2018
FDA's Letter: FDA has no questions (in PDF) (53 kB)